Facing high costs and drug shortages, they turned to compounded weight loss drugs online. An FDA ban might end that.
Is the era of sourcing cheaper weight loss drugs from the internet over? High demand for GLP-1 agonists — prescription drugs ...
Why cheaper alternatives to weight-loss drugs like Wegovy, Zepbound will be tougher to get
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Hims & Hers’ Weight-Loss Empire Hits a Gut-Wrenching End
Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...
Here’s why Hims & Hers stock price has crashed: buy the dip?
Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Hims & Hers Health, Inc. stock faces volatility after an FDA halt on its GLP-1 drug. Click here to find out why HIMS stock is ...
Healthline8d
Compounding Pharmacies to Stop Making Ozempic, Zepound Knockoffs: What to Know
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...